KCND3 Gene Spinocerebellar Ataxia Type 22 (Autosomal Dominant) Genetic Test in UAE

The KCND3 gene encodes the Kv4.3 potassium voltage-gated channel subunit that is highly expressed in cerebellar Purkinje neurons. Pathogenic variants in this gene disrupt the intrinsic firing properties of Purkinje cells, leading to progressive cerebellar degeneration and adult-onset ataxia. Because the condition follows autosomal dominant inheritance, each child of an affected parent has a 50% chance of inheriting the pathogenic variant. Definitive genetic testing confirms the clinical suspicion and enables accurate reproductive risk assessment for family planning.

A standard peripheral blood draw (2–3 mL in EDTA tube), a dried blood spot on an FTA card, or previously extracted high-quality genomic DNA can be used as the specimen. Our DHA-licensed phlebotomist performs a VIP mobile phlebotomy visit at your home or office daily from 8 AM to 11 PM using temperature-controlled cold-chain transport. The sample is received by our ISO 9001:2015-certified laboratory, where targeted NGS sequencing and confirmatory Sanger validation are completed within 3–4 weeks. All specimens are logged with a unique barcode for full chain-of-custody traceability.

A positive result identifies the exact DNA variant responsible for the ataxia phenotype, enabling targeted neuro-rehabilitation strategies, eligibility screening for clinical trials, and cascade testing of at-risk relatives. If negative, it effectively rules out KCND3-associated SCA22, though your neurologist may recommend broader ataxia gene panels or whole exome sequencing if the clinical suspicion remains high. Regardless of the result, a board-certified genetic counselor from DNA Labs UAE will schedule a dedicated telephonic session to explain your report in plain language and coordinate appropriate follow-up with your referring physician.